CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 119 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04204434
NCT04204434N/ACompleted

Biomarkers For Immune Checkpoint Inhibitors

Rhode Island Hospital·observational·Posted Dec 19, 2019·Updated Aug 13, 2024

In Brief

An observational study for Advanced Cancer and Neoplasms. Completed, enrolled 119 participants across 2 sites.

Detailed Summary

This is a laboratory, non-treatment study. Immune checkpoint inhibitors are a type of immunotherapy that stimulates a patients immune system to fight their cancer. Immune checkpoint inhibitors are standard, FDA approved treatment for certain types of cancers such as melanoma, lung cancer, kidney cancer and bladder cancer. The laboratories of Dr. Jack Elias and Dr. Chun Geun Lee at Brown University are studying how immune checkpoint inhibitors work.Kintai Therapeutics is a biotech company in Cambridge Massachusetts that will focus on the molecules present in the GI tract, including the stomach, small intestine and colon.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsBrown University

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedDec 19, 2019
Enrollment StartNov 29, 2016
Primary CompletionDec 31, 2021
Study CompletionApr 26, 2024
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 6.5 years ago